Similarly, IL-6 levels were significantly reduced in the semaglutide-treated group compared to the T2DM group (p < 0.001), while dapagliflozin also lowered IL-6 levels, though to a lesser extent (ns). This evidence concerns the gene IL6 and type 2 diabetes mellitus.